<DOC>
	<DOCNO>NCT01890785</DOCNO>
	<brief_summary>Compare pharmacokinetic profile content empty soft food orange juice compare SPD489 swallow intact capsule .</brief_summary>
	<brief_title>Bioavailability Study SPD489 Administered With Two Different Means Administration Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>1 . Age 1855 year inclusive time consent . The date signing informed consent define begin Screening Period . This inclusion criterion assess first screen visit . 2 . Willingness comply applicable contraceptive requirement fo protocol : Male , Non pregnant , non lactate female Females must least 90 day post partum nulliparous 3 . Must consider `` healthy '' . Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead electrocardiogram , hematology , blood chemistry , urinalysis . 4 . An understanding , ability , willingness fully comply study procedure restriction 5 . Ability provide write , personally sign , date informed consent participate study , accordance International Conference harmonisation Good Clinical Practice Guideline E6 ( 1996 ) applicable regulation , complete study relate procedure 6 . A body mass index 18.530.0kg/mÂ² inclusive . This inclusion criterion assess first screen visit . 7 . A hemoglobin value &gt; =12.0g/dL Screening Visit Day 1 Treatment Period 1 . 8 . Ability swallow dose investigational product accord study condition . Subjects exclude study follow criterion meet Screening Visit Day 1 Treatment Period 1 ( reassess ) : 1 . Current recurrent disease ( eg , cardiovascular , renal , liver , gastrointestinal , malignancy , condition ) could affect action , absorption , disposition investigational product , could affect clinical laboratory assessment . 2 . Current relevant history physical psychiatric illness , medical disorder may require treatment make subject unlikely fully comply requirement study complete study , condition present undue risk investigational product study procedure . 3 . Significant illness , judge investigator , within 2 week first dose investigational product . 4 . History significant anxiety , tension , agitation assess investigator . 5 . History current diagnosis glaucoma . 6 . History seizure disorder ( infantile febrile seizure ) , tic disorder , current diagnosis and/or know family history Tourette 's Disorder . 7 . History presence know structural cardiac abnormality , syncope , cardiac conduction problem , exerciserelated cardiac event , clinically significant bradycardia . 8 . History symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , transient ischemic attack stroke serious cardiac problem may place increased vulnerability sympathomimetic effect stimulant drug . 9 . History control uncontrolled hypertension rest supine systolic blood pressure &gt; 139mmHg diastolic blood pressure &gt; 89mmHg . 10 . Known family history sudden cardiac death ventricular arrhythmia . 11 . Currently consider suicide risk , previously make suicide attempt , history , currently demonstrate suicidal ideation . 12 . Current use medication ( include prescription , overthecounter , herbal homeopathic preparation ) exception hormonal replacement therapy hormonal contraceptive ( current use define use within 14 day first dose investigational product ) . 13 . Use medication know inhibit induce cytochrome P450 ( CYP450 ) enzymes responsible metabolism investigational product within 14 day first dose investigational product . 14 . Known suspected intolerance hypersensitivity investigational product , closely related compound , state ingredient . 15 . Known suspected intolerance hypersensitivity orange juice vanilla yogurt . 16 . History alcohol substance abuse within last year . 17 . A positive screen alcohol drug abuse Screening Visit Day 1 Treatment Period 1 . 18 . Male subject consume 3 unit alcohol per day . Female subject consume 2 unit alcohol per day . ( 1 alcohol unit=1 beer=1 wine [ 5oz ] =one liquor [ 1.5 oz ] =0.75oz alcohol. ) . 19 . A positive human immunodeficiency virus antibody screen , Hepatitis B surface antigen , Hepatitis C virus antibody screen . 20 . Use tobacco form ( eg , smoke chew ) nicotinecontaining product form ( eg , gum , patch ) within 30 day prior first dose investigational product . 21 . Routine consumption 2 unit caffeine per day subject experience caffeine withdrawal headache history caffeine withdrawal headache . ( One caffeine unit contain follow item : one 6oz cup coffee , two 12oz can cola , one 12oz cup tea , three 1oz chocolate bar . Decaffeinated coffee , tea , cola consider contain caffeine ) . 22 . Donation blood blood product ( eg , plasma platelet ) within 60 day prior first dose investigational product . 23 . Use another investigational product within 30 day prior receive first dose investigational product active enrollment another drug vaccine clinical study . 24 . Substantial change eat habit within 30 day prior receive first dose investigational product , assessed investigator . 25 . An inability follow standardize diet meal schedule inability fast , require study . 26 . Prior screen failure , randomization , participation , enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>